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Zn(II) mediates vancomycin 
polymerization and potentiates its 
antibiotic activity against resistant 
bacteria
Ashraf Zarkan1,5, Heather-Rose Macklyne  1, Dimitri Y. Chirgadze1, Andrew D. Bond2,  
Andrew R. Hesketh1,3 & Hee-Jeon Hong1,4
Vancomycin is known to bind to Zn(II) and can induce a zinc starvation response in bacteria. Here we 
identify a novel polymerization of vancomycin dimers by structural analysis of vancomycin-Zn(II) 
crystals and fibre X-ray diffraction. Bioassays indicate that this structure is associated with an increased 
antibiotic activity against bacterial strains possessing high level vancomycin resistance mediated by 
the reprogramming of peptidoglycan biosynthesis to use precursors terminating in D-Ala-D-Lac in 
place of D-Ala-D-Ala. Polymerization occurs via interaction of Zn(II) with the N-terminal methylleucine 
group of vancomycin, and we show that the activity of other glycopeptide antibiotics with this feature 
can also be similarly augmented by Zn(II). Construction and analysis of a model strain predominantly 
using D-Ala-D-Lac precursors for peptidoglycan biosynthesis during normal growth supports the 
hypothesis that Zn(II) mediated vancomycin polymerization enhances the binding affinity towards 
these precursors.
Antibiotics are a diminishing resource, with the emergence and spread of resistance in bacterial populations 
currently outstripping the pace of discovery and approval of novel compounds. There is consequently a renewed 
interest in finding leads for novel antibacterial activities, and for the development of methods capable of enhanc-
ing the effectiveness of existing treatments.
Vancomycin, a natural product glycopeptide antibiotic, is a last resort treatment for serious infections 
caused by Gram-positive bacterial pathogens, particularly those associated with MRSA (Methicillin resistant 
Staphylococcus aureus) or drug-resistant enterococci. The emergence of vancomycin resistance in these patho-
genic strains is however threatening to reduce its usefulness as a front-line therapy1, 2. Vancomycin acts by binding 
to the D-Ala-D-Ala termini of bacterial cell wall peptidoglycan (PG) and of the PG precursor Lipid II, thereby 
compromising the synthesis and strength of the bacterial cell wall and leading to reduced growth and cell death3. 
A small number of semisynthetic second-generation lipoglycopeptide antibiotics have recently been developed 
to improve the treatment options available for Gram-positive infections, but possess the same mode of action as 
the parent template glycopeptide vancomycin4, 5.
Vancomycin has recently been characterized as a zinc chelator, binding Zn(II) via the N-terminal methylleu-
cine amino acid group and inducing a zinc starvation response in treated bacteria6, 7. Although it is not common, 
some antibiotics are known to require metal ions for their activity8. Bacitracin requires binding of divalent metal 
ions for sequestration of its molecular target undecaprenyl pyrophosphate, with Zn(II) being most effective at sta-
bilizing complex formation through neutralization of the pyrophosphate charge9. Quinolone antibiotics also use 
metal ions to help bind their target molecules, DNA topoisomerase enzymes10, 11. When not required to mediate 
target binding, interaction of metal ions with antibiotics can provide an additional mode of antibacterial action, 
as seen for example with the sequestration of iron by tetracyclines12. Here we report for the first time that zinc 
potentiates the antibiotic activity of vancomycin, and certain other glycopeptide antibiotics, specifically against 
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bacterial strains exhibiting inducible glycopeptide resistance. Structural analysis indicates a novel polymerized 
arrangement of vancomycin molecules resulting from the interaction with Zn(II), and we use data from in vitro 
and in vivo studies to propose a new mode of action for this vancomycin polymer. We consider the significance of 
the interaction with Zn(II) for patient treatment.
Results
Zn(II) potentiates the activity of vancomycin against inducibly resistant bacteria. To investi-
gate the effect of the interaction of Zn(II) with vancomycin on antibiotic activity, we performed susceptibility 
tests using strains known to be inducibly resistant to vancomycin, and isogenic relatives lacking this resistance. 
Streptomyces coelicolor M60013 and Enterococcus faecalis JH2-2::I14 both possess dedicated resistance genes which 
direct the synthesis of modified PG precursors ending in D-Ala-D-Lac, to which glycopeptide antibiotics exhibit 
very low binding affinities. Expression of resistance is induced by vancomycin via a two-component regulatory 
system composed of a sensor kinase (VanS) and a cognate response regulator (VanR) that acts as a transcriptional 
activator when phosphorylated. Strikingly, co-administration of vancomycin with increasing concentrations of 
zinc sulphate (0-200 μM) increased the zone of growth inhibition against vancomycin-resistant S. coelicolor M600 
in a paper disc diffusion assay (Fig. 1a). This effect is specific for Zn(II). Both Ni(II) and Cu(II), the latter known 
to more strongly interact with vancomycin than Zn(II)7, 15, 16, had no effect on the activity of vancomycin. As 
expected, the presence of Zn(II) also enhanced the antibiotic activity of bacitracin9, but did not influence kan-
amycin (Fig. 1a). 200 μM Zn(II) also failed to increase the antibacterial activity of ramoplanin, moenomycin, 
novobiocin, apramycin and tunicamycin against S. coelicolor M600 (Supplementary Fig. 1), indicating that the 
concentration of Zn(II) used in the experiments are in the non-toxic range. Teicoplanin, a naturally occurring 
lipoglycopeptide antibiotic, also showed no increase in activity in the presence of Zn(II) (Fig. 1a). Importantly, 
the potentiation of vancomycin activity by Zn(II) was also observed when using E. faecalis JH2-2::I as the test 
strain indicating that this is a more general phenomenon (Fig. 1b). Minimal inhibitory concentration (MIC) 
measurements attribute a 4- to 8-fold increase in susceptibility towards vancomycin to Zn(II) in E. faecalis JH2-
2::I and S. coelicolor M600, respectively (Fig. 1b). Notably, the use of the vancomycin-sensitive strains S. coelicolor 
J320117 and E. faecalis JH2-214 abolished the influence of Zn(II) on vancomycin activity, but had no abrogating 
effect on the enhancement of bacitracin activity (Fig. 1b). The VanRS two-component regulatory system required 
for inducing vancomycin resistance is deleted in S. coelicolor J3201, while E. faecalis JH2-2 lacks the transposon 
carrying all the vancomycin resistance genes that is present in JH2-2::I. This implies that the potentiation of van-
comycin by Zn(II) is directly related to the functioning of the vancomycin resistance system.
Only glycopeptide antibiotics which are capable of activating inducible resistance are potenti-
ated by Zn(II). To define the relationship between the effect of Zn(II) on glycopeptide antibiotic activity and 
induction of glycopeptide resistance, a broader panel of natural glycopeptides were assayed for activity in different 
streptomycete indicator strains (Fig. 2a and Supplementary Fig. 2). Glycopeptide-strain combinations where the 
strength of induction via the VanS sensor kinase had previously been characterized13, 17–21 were selected, and 
assayed for any potentiation by Zn(II). In strains possessing functional inducible glycopeptide resistance systems, 
Zn(II)-dependent enhancement of glycopeptide antibiotic activity was closely correlated with the ability of the 
glycopeptide to act as an inducer of glycopeptide resistance. Thus in S. coelicolor M600, balhimycin and vanco-
mycin are both the strongest inducers and exhibit the most marked potentiation of activity by Zn(II). In con-
trast, poor inducers of VanS in this strain background i.e. ristocetin, A47934, chloroeremomycin, and teicoplanin 
show only small or negligible changes in activity on addition of Zn(II) (Fig. 2a). This correlation is confirmed by 
observations in Streptomyces toyocaensis, where, in contrast to S. coelicolor M600, differences in the amino acid 
sequence of the VanS sensor kinase (VansSst) dictate that vancomycin is a poor inducer of resistance and A47934 
the strongest inducer (Supplementary Fig. 2)19–21. The influence of Zn(II) on the activity of these antibiotics is also 
reversed between the two strains, with vancomycin activity against S. toyocaensis no longer affected by Zn(II) but 
the activity of A47934 being most markedly increased. Also consistent with these observations, control strains 
lacking any inducible glycopeptide resistance, S. coelicolor J3201 and Streptomyces avermitilis, exhibited no inter-
action between Zn(II) and glycopeptide activity (Fig. 2a and Supplementary Fig. 2).
Bioassay results indicate that in the S. coelicolor M600 background the activities of vancomycin and balhimy-
cin are each capable of being enhanced by Zn(II) (Fig. 2a). Vancomycin is known to bind Zn(II)7. To determine 
whether balhimycin can participate in a similar physical interaction, affinity column chromatography, fluorome-
try and Calf Intestinal Alkaline Phosphatase (CIAP) inhibition assays were performed as previously described for 
vancomycin7 (Fig. 2b and Supplementary Figs 3–5). All three methods indicated an interaction with Zn(II) that 
is notably stronger than that observed for teicoplanin whose antibiotic activity is influenced only marginally by 
Zn(II). Zn(II)-dependent enhancement of glycopeptide activity therefore appears to require both the ability of the 
antibiotic to induce glycopeptide resistance via VanS, and physical interaction with Zn(II).
The potentiation of vancomycin activity by Zn(II) requires remodelling of PG termini to 
D-Ala-D-Lac. Three different hypotheses could explain the effect of Zn(II) on vancomycin (and other gly-
copeptide) antibiotic activity in inducibly resistant bacterial strains, and these were tested experimentally. An 
inhibitory effect on the Zn(II)-dependent D-Ala-D-Ala dipeptidase activity of the VanX vancomycin resistance 
enzyme was ruled out by analysis of the S. coelicolor ∆vanX mutant J322513 which was found to respond to 
Zn(II)-vancomycin in the same way as the M600 parent strain (Supplementary Fig. 6). The hypothesis that inter-
action of vancomycin with Zn(II) increased sensitivity by inhibiting activation of the VanS sensor kinase by the 
glycopeptide was also eliminated through the analysis of mutant strains (Supplementary Fig. 7). vanS mutants of 
S. coelicolor (J3200)17 and E. faecalis (JH2-2::C1)14 which exhibit constitutively active glycopeptide resistance, with 
no requirement for the presence of antibiotic inducer, again show a normal enhancement of vancomycin activity 
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in response to Zn(II) (Supplementary Fig. 7). The remaining possibility is that interaction of vancomycin with 
Zn(II) increases the inhibition of PG biosynthesis that takes place using the remodelled vancomycin-resistant 
PG precursors possessing D-Ala-D-Lac termini. To investigate this hypothesis we exploited the activities of the 
homologous enzymes VanA and DdlA in S. coelicolor. VanA is a non-essential bifunctional D-Ala-D-Ala and 
D-Ala-D-Lac ligase enzyme which preferentially synthesizes D-Ala-D-Lac in the presence of D-Lactate (D-Lac), 
and supplies the substrate required for the remodelling of PG biosynthesis in response to vancomycin13, 22. In con-
trast, DdlA encodes the essential D-Ala-D-Ala ligase activity responsible for cell wall formation during normal 
growth using PG precursors with D-Ala-D-Ala termini22, 23. To generate a strain (H7400) constitutively using PG 
terminating in D-Ala-D-Lac during normal growth, we introduced the vanA gene under the control of the strong 
and constitutive ermE promoter (ermEp) into the S. coelicolor ∆vanRS mutant J3201, then successfully deleted 
the normally essential ddlA gene. An analogous strain (H7300) expressing ddlA from the ermEp was also gen-
erated as a control. Use of the ∆vanRS mutant background ensures that there is no contribution from the native 
vancomycin-inducible vanA gene. Vancomycin antibiotic activity was potentiated by Zn(II) only in strain H7400 
where PG precursors terminating in D-Ala-D-Lac are used for cell wall biosynthesis, not in H7300 which uses PG 
Figure 1. Zinc potentiates antibiotic activity of vancomycin against vancomycin-resistant bacteria. (a) The 
effect of Zn(II), Cu(II) and Ni(II) on the activity of teicoplanin (T), vancomycin (V), bacitracin (B) and 
kanamycin (K) against wild-type S. coelicolor M600. (b) The effect of Zn(II) on the activity of teicoplanin (T), 
vancomycin (V), bacitracin (B) and kanamycin (K) against vancomycin-sensitive (VanS) or vancomycin-
resistant (VanR) strains of S. coelicolor and E. faecalis. The concentration of each antibiotic used is listed in 
Supplementary Table 1. The table shows the effect of Zn(II) on MIC values (μg ml−1) for vancomycin in resistant 
and sensitive strains.
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precursors terminating in D-Ala-D-Ala (Fig. 3a). This effect was further enhanced when the growth medium was 
supplemented with D-Lactate to promote the D-Ala-D-Lac ligase activity of VanA (Fig. 3a). This implies that the 
interaction with Zn(II) can specifically increase the binding affinity of vancomycin for PG molecules terminating 
in D-Ala-D-Lac. This interpretation is supported by in vitro fluorometric analysis which shows a marked quench-
ing of vancomycin fluorescence on addition of Zn(II) to a solution containing vancomycin and D-Ala-D-Lac, but 
not vancomycin in the presence of D-Ala-D-Ala (Fig. 3b). In contrast, addition of Zn(II) to vancomycin enhances 
fluorescence in the control indicating different binding (Fig. 3b).
Zn(II) mediates polymerisation of vancomycin. The interaction of vancomycin with Zn(II) is 
associated with a novel D-Ala-D-Lac binding activity. To investigate the structural basis for this activ-
ity we have crystallized the vancomycin-Zn(II) complex. Our first attempt generated a crystal structure for a 
vancomycin-Zn(II)-citrate complex containing two independent vancomycin molecules in an asymmetric unit 
with space group C222, plus a separate complex of Zn(II) coordinated by two citrate molecules and a polyeth-
ylene glycol molecule (Supplementary Fig. 8a and Supplementary Table 2). This dimeric arrangement of vanco-
mycin is identical to that previously reported by Schäfer and colleagues (space group P 43212) (Supplementary 
Fig. 8c)24. Subsequent crystallization in the absence of citrate successfully generated a clean vancomycin-Zn(II) 
crystal structure (Fig. 4a and Supplementary Fig. 8b). The structure revealed two independent vancomycin mol-
ecules in space group H3, and a Zn(II) ion coordinated by two water molecules and two atoms derived from 
the N-terminal methylleucine group of vancomycin, including one amino nitrogen and one carboxyl oxygen 
(Fig. 4a, Supplementary Fig. 8b and Supplementary Table 2). This binding site for Zn(II) to the vancomycin 
molecule is entirely consistent with that predicted from our previous NMR solution structural studies, and is 
distinct from the binding site for Cu(II) (Fig. 4b)7, 15. The presence of Zn(II) allows vancomycin to adopt a novel 
Figure 2. Zn(II) potentiates the activity of glycopeptide antibiotics that are both strong inducers for 
resistance and which interact with Zn(II). (a) The effect of Zn(II) on the activity of ristocetin (R), A47934 (A), 
chloroeremomycin (C) and balhimycin (Bl) against vancomycin-resistant and -sensitive S. coelicolor strains. 
The table summarizes the bioassay results shown above, presenting the influence of Zn(II) on antibiotic activity 
against an index summarizing the ability of each antibiotic to induce the VanS sensor in S. coelicolor, obtained 
from previous studies13, 17–21. (b) Metal affinity chromatography to measure the interaction of balhimycin and 
teicoplanin with Zn(II), Cu(II) or Ni(II). Elution of teicoplanin or balhimycin from the columns was quantified 
by the analysis of 0.5 ml fractions at OD282 and a bioassay against a vancomycin sensitive S. coelicolor ∆vanRS 
mutant strain (Supplementary Fig. S4).
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conformation not previously observed in reported vancomycin crystal structures (Supplementary Fig. 8b), and is 
distinct from the conformation of the vancomycin-Cu(II) complex in which two independent vancomycin mol-
ecules are arranged in space group C2 (Supplementary Fig. 8d)16. This novel conformation allows the assembly 
of repeated vancomycin dimers held together by coordination with Zn(II) to generate a vancomycin polymer 
(Fig. 4a). Fibre X-ray diffraction, a technique to study the molecular structure of long assemblies of identical 
subunits25, confirmed the polymerization of vancomycin by Zn(II) (Supplementary Fig. 9). Analysis of a sample 
containing both vancomycin and Zn(II) generated a diffraction pattern consisting of three concentric reflection 
rings at 25 Å, 11 Å and 8 Å of Braggs’ interplanar distances, consistent with the presence of repetitive polymer 
fibres with a low degree of alignment26, 27. These were completely absent in similar analysis of a control sample of 
vancomycin lacking Zn(II) (Supplementary Fig. 9).
Discussion
High-level glycopeptide resistance in Gram-positive bacteria is due to the replacement of the D-Ala-D-Ala termi-
nus of PG precursors with D-Ala-D-Lac, to which the antibiotics exhibit lower binding affinities4. Replacement 
with D-Ala-D-Ser can also occur but generates markedly lower resistance due to production of a smaller defect 
in antibiotic binding. The identification of a lead glycopeptide structure with increased activity against cell wall 
biosynthesis proceeding via PG precursors with D-Ala-D-Lac termini is therefore of significant interest. The 
novel polymerization of vancomycin mediated by interaction with Zn(II) is associated with increased antibiotic 
activity against model D-Ala-D-Lac-based glycopeptide resistant strains, including an E. faecalis VRE strain. 
Interestingly, a synthetic polymer of vancomycin monomers with enhanced potency against VRE has previously 
been reported, and surface plasmon resonance studies also indicated an increased binding affinity between the 
Figure 3. Interaction of Zn(II) with vancomycin increases its activity against glycopeptide-resistant 
peptidoglycan precursors terminating in D-Ala-D-Lac, and changes its binding. (a) The effect of Zn(II) on 
the activity of teicoplanin (T), vancomycin (V), bacitracin (B) and kanamycin (K) against S. coelicolor strains 
engineered to constitutively produce peptidoglycan precursors terminating in D-Ala-D-Lac (H7400) or D-Ala-
D-Ala (H7300). Supplementation with D-lactate (D-Lac; 10 mM) promotes the major D-Ala-D-Lac ligase 
activity of VanA at the expense of the minor D-Ala-D-Ala activity. (b) Fluorometric analysis indicating a change 
in the interaction between vancomycin and D-Ala-D-Lac, but not D-Ala-D-Ala, in the presence of Zn(II). The 
left panel shows the effect of Zn(II) on vancomycin fluorescence for comparison.
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polymer and a VRE cell wall mimic containing D-Ala-D-Lac28. In this study, Zn(II) causes polymerization of 
vancomycin dimers, with the metal ion holding repeated dimeric units in place via interaction with nitrogen and 
oxygen atoms in the N-terminal methylleucine moiety (Fig. 4).
Other glycopeptide or lipoglycopeptide antibiotics which possess the methylleucine interaction site would also 
be expected to bind Zn(II) and may also be susceptible to similar polymerization and enhancement of antibiotic 
activity. Consistent with this, Zn(II) was able to increase the activity of two antibiotics with the methylleucine group, 
balhimycin and A47934, but had no effect on either teicoplanin or ristocetin which lack this feature (Supplementary 
Table 3). In vitro assays also demonstrated markedly stronger binding of Zn(II) to balhimycin compared to teico-
planin. Chloroeremomycin does possess a potential binding site but Zn(II) did not produce an effect in a bio-
assay against S. coelicolor M600 since the antibiotic is not a good inducer of the D-Ala-D-Lac resistance system. 
Interestingly, of the three new semi-synthetic lipoglycopeptide antibiotics being brought into clinical use, both orita-
vancin and telavancin retain the methylleucine present in vancomycin and therefore potentially also retain the abil-
ity to interact with Zn(II). Dalbavancin has a structure related to teicoplanin and would not be predicted to interact.
Due to the well-known effect of Zn(II) on bacitracin antibiotic activity, topical treatments for application to 
wound infections come pre-formulated as bacitracin-zinc. The results of this study suggest that a similar approach 
may also be beneficial for vancomycin to augment activity against vancomycin resistant pathogens. This could be 
evaluated for clinical significance using a suitable infection model. Some of the known side effects of vancomycin 
in long term treatments also coincidently overlap with aspects of zinc deficiency syndrome, such as nephrotoxic-
ity or muscle spasm29, 30. Careful co-administration of vancomycin with a Zn(II) additive could therefore be help-
ful for both antibiotic activity and the alleviation of toxic side effects. Further studies to determine the structure 
of the tertiary vancomycin-Zn(II)-D-Ala-D-Lac complex will be necessary to fully understand the nature of the 
Figure 4. Zn(II) interacts with the N-terminal methylleucine of vancomycin to produce a novel polymer 
of dimers. (a) Crystal structure of vancomycin-Zn(II) determined by X-ray crystallography. Zn(II) ions 
(indicated by arrows) hold dimers of vancomycin in a polymeric structure, as also illustrated in the schematic 
representation showing the arrangement of vancomycin molecules (coloured rectangles, stacked in dimers) and 
Zn(II) ions in the polymer. The inset shows Zn(II) joining adjacent vancomycin dimers via ionic interaction 
with the carbonyl (in red) and secondary amine (in blue) groups of the N-terminal methylleucine group. (b) 
Chemical structure of vancomycin indicating the site of interaction with Zn(II) relative to Cu(II).
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binding to D-Ala-D-Lac PG precursors, and to be able to further exploit the enhanced affinity of polymerized 
vancomycin and other glycopeptide antibiotics toward D-Ala-D-Lac.
Methods
Bacterial strains, plasmids, oligos, antibiotics and culture conditions. The bacterial stains, plas-
mids and oligos used in this study are described and listed in Supplementary Table 4. A47934 was prepared from 
the producer strain S. toyocaensis as described previously31. Balhimycin and chloroeremomycin were kind gifts 
from Andy Truman. All other antibiotics used for this study were purchased from Sigma-Aldrich. Except where 
detailed below, media and culture conditions were as previously described32.
Antibiotic susceptibility tests. All susceptibility tests, including the antibiotic disc diffusion assays and 
MIC determinations, were performed on MMCGT agar medium33 supplemented with the required concentra-
tion of metal sulphate. Results were scored after 2–4 days of incubation at 30 °C. For the antibiotic disc diffusion 
assay, for S. coelicolor, 0, 50, 100, 150 and 200 μM of metal sulphate was added to the media, and for S. avermitilis 
0, 100 and 200 μM of metal sulphate was used. For S. toyocaensis, the assay was performed using 0, 50 and 100 μM 
of metal sulphate. E. faecalis strains were exposed to 0, 100, 200, 300 and 400 μM metal sulphate. Concentrations 
beyond these maximum levels can cause toxicity and were avoided. For the bioassay of all Streptomyces strains, 
approximately 107 spores were used to seed the test plates. For the E. faecalis strains, approximately 107 cfu from 
an overnight LB liquid culture were spread on the MMCGT medium. The concentrations of antibiotics used in 
the bioassays are listed in Supplementary Table 1. For the determination of the vancomycin MICs, Etest strips pur-
chased from Biomerieux were used. All bioassays were performed at least three times and representative results 
are presented. The degree of relative variation for the inhibitory halo size in plate diffusion tests was less than 10%.
Construction of S. coelicolor H7300 and H7400. S. coelicolor H7300 (∆vanRS ∆ddlA + ermEp-ddlA) 
and H7400 (∆vanRS ΔddlA + ermEp-vanA), were constructed from S. coelicolor ∆vanRS J320117 as follows. 
Initial transformation with pGN8 (pIJ10257 ermEp-ddlA)22 or pGN17 (pIJ10257 ermEp-vanA)22 generated 
strains H7100 and H7200, respectively. Deletion of the ddlA gene in H7100 and H7200 was then accomplished by 
PCR-directed mutagenesis as described previously22, creating H7300 and H7400, respectively.
Affinity column chromatography. Metal affinity column chromatography experiments were performed 
as described previously7. HiTrap Chelating HP (GE healthcare) columns were initially washed with 5 ml of MilliQ 
water with a flow rate of 1 ml min−1 then loaded with 500 μl of 100 mM copper, nickel or zinc sulphate solutions. 
A column loaded with buffer solution was used as an uncharged negative control. Columns were washed again 
with 5 ml of MilliQ water then equilibrated with 10 ml of binding buffer (20 mM NaH2PO4/Na2HPO4 (pH 7.4), 
200 mM NaCl, 10% Glycerol, 0.1% Triton-X-100). 150 μl of 10 mM balhimycin or teicoplanin was applied to each 
column and elution performed using 5 ml of binding buffer followed by 5 ml of binding buffer supplemented with 
50 mM imidazole. Sixteen 0.5 ml fractions were collected (after discarding the dead volume of the column) and 
the relative abundance of antibiotic in each fraction was measured at OD282 after 5x dilution in water. Aliquots 
of the same diluted fractions were also analysed in a bioassay. For this, 20 μl was applied to freshly prepared 
MMCGT bioassay plates seeded with ~107 spores of a vancomycin-sensitive S. coelicolor ∆vanRS strain (J3201)17. 
The results were scored after incubation at 30 °C for 2–4 days.
Fluorometry. Fluorometric analysis was performed in 100 mM Tris-Cl (pH7.3) according to the 
method described previously7 using a PerkinElmer LS55 fluorescence spectrometer (Waltham, MA, USA) 
set to a 280 nm excitation wavelength; 5 nm slit width; 300–450 nm emission scan range; and 50 nm min−1 
scan speed. Vancomycin solutions were supplemented with 50 µM of Ac-Lys(Ac)-D-Ala-D-Ala-OH or 
Ac-Lys(Ac)-D-Ala-D-Lac-OH (Bachem) where indicated. Zn(II) was added to the required concentration from 
a 50 mM stock solution of zinc sulphate heptahydrate in deionized water.
Crystallization, data collection and refinement. Vancomycin hydrochloride (Sigma, V2002) and 
zinc sulphate heptahydrate (Sigma, Z4750) were purchased from Sigma and used without further purification. 
Vancomycin was used at a concentration of 50 mg ml−1 in 10 mM HEPES buffer at pH 7.022, and Zn(II) added to a 
10-fold molar excess, adjusting the pH to 7.0 as required. Any insoluble material was removed by centrifugation, 
and the supernatant was used to set up MRC 2-drop crystallisation trial plates containing conditions from the 
JCSG + (Molecular Dimensions) or PEGs I (Qiagen) crystallisation suites. Plates were loaded with two drops per 
reservoir, each containing 0.2 μl sample + 0.2 μl of crystallisation suite mix, using a Mosquito® crystallisation 
robot (TTP Labtech). The plates were then incubated at 19 °C in a Rock Imager Hotel/Imager (Formulatrix) and 
imaged (visual and UV) over a period of 34 days. Any crystals formed were harvested using 0.2–0.3 ml cryoloops 
(Hampton) and cryoprotectant solution containing 26% ethylene glycol and reservoir solution. Harvested crys-
tals were plunged into liquid nitrogen and either stored or used for diffraction experiments straight away. Well 
A3 of the JCSG + plate, the reservoir of which contains 0.2 M di-ammonium hydrogen citrate salt [(NH4)2H 
Cit (C6H5O7)] + 20% (w/v) PEG 3350, produced the crystal found to be a tertiary vancomycin-Zn(II)-citrate 
complex. The desired vancomycin-Zn(II) crystal was obtained from well F8 of the PEGs I plate, from a reser-
voir comprising 0.2 M magnesium formate salt + 20% (w/v) PEG 3350. Diffraction data were collected at the 
Diamond Synchrotron Facility (Oxford, UK). A summary of the conditions for the data collection and the struc-
ture refinement parameters are given in Supplementary Table 2. The crystal structures were solved either by 
direct methods or using the single wavelength anomalous dispersion (SAD) method, with the chlorine atoms as 
the anomalous scatters (Cl-SAD). Model coordinates have been deposited in the Protein Data Bank (PDB) under 
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accession number 5M2H for the vancomycin-Zn(II)-citrate complex and under accession number 5M2K for the 
vancomycin-Zn(II) complex.
Fibre X-ray diffraction. X-ray diffraction studies were performed at the Crystallographic X-ray facil-
ity, Department of Biochemistry, University of Cambridge using an X8 Proteum (Bruker AXS). Fibre samples 
were placed in the X-ray beam and the diffraction data were collected with a sample-to-detector distance of 120 
mm and an exposure time of 120 sec. Fibre samples for analysis were generated from solutions of vancomycin 
(5 mg ml−1 solution of vancomycin hydrochloride in 10 mM HEPES buffer at pH 7.0) or vancomycin-Zn(II) (van-
comycin solution plus a 10-fold molar excess of zinc sulphate heptahydrate (Sigma, Z4750) in 10 mM HEPES 
buffer at pH 7.0) as described in the Supplementary Methods.
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